The Ritedose Corporation

The Ritedose Corporation is a leading provider of sterile contract development and manufacturing services, focusing on advanced Blow-Fill-Seal technology for pharmaceutical products. The Ritedose Corporation was founded in 1995 and is headquartered in Columbia, US. The company specializes in sterile contract development and manufacturing services, with a focus on inhalation solutions. In January 2022, AGIC Capital and Humanwell Healthcare sold the company to Novo Holdings, a strategic move aimed at expanding its core business and developing new operations.

The current CEO is Jody Chastain, who has led the company through various strategic initiatives. Ritedose has successfully completed a total of 3 funding deals, including the most recent fund-raising round, a Secondary Buyout of USD 600. 00 mn led by AGIC Capital. This latest funding round brought the total amount raised to USD 600.

00 mn. The Ritedose Corporation specializes in sterile contract development and manufacturing services, primarily utilizing Blow-Fill-Seal (BFS) technology. This automated process involves blowing extruded polymer into molds, filling them with pharmaceutical products, and sealing them continuously. Ritedose's core product offerings include a range of inhalation solutions and other sterile medications targeted at addressing critical healthcare needs, particularly for patients with respiratory conditions.

The company has delivered over 12 billion doses since its inception, catering to a diverse clientele that includes wholesalers, major retail pharmacy chains, and hospitals across various regions in the US. Ritedose generates revenue through its contract development and manufacturing operations, engaging in B2B transactions primarily with pharmaceutical companies, wholesalers, and healthcare providers. The company emphasizes partnerships with its clients, ensuring reliable quality for both branded and generic inhalation solutions. Transactions typically involve supplying customized sterile medications, with clients placing bulk orders tailored to their specific needs.

Ritedose's flagship products, including inhalation solutions like Cromolyn Sodium and Arformoterol Tartrate, are integral to its offerings, providing essential therapeutic options for managing respiratory conditions. The acquisition by Novo Holdings in January 2022 will enable The Ritedose Corporation to expand its core business and develop new operations to fuel additional growth. The company aims to introduce new products and expand into new geographic markets. Specific details on upcoming product launches have not been disclosed, but the overall strategy centers on leveraging recent funding to enhance operational capabilities and market reach.